Feature Channels: ASCO Meeting News

Filters close
Released: 6-Jun-2024 10:05 AM EDT
Breakthroughs in Breast Cancer: Susan G. Komen(R) Scholars and Studies Highlighted at ASCO 2024
Susan G. Komen

Scholars and studies funded by Susan G. Komen(R), the world’s leading breast cancer organization, showcased cutting-edge breast cancer research aimed at advancing the field at the ASCO Annual Meeting 2024. Organized by the American Society of Clinical Oncology, this premier conference annually convenes over 40,000 oncologists and stakeholders worldwide.

Released: 4-Jun-2024 8:05 AM EDT
AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored autologous GPC3 CAR-T, in patients with advanced hepatocellular carcinoma, at ASCO Annual Meeting 2024
AbelZeta Pharma, Inc.

CAR031 study at 9.03-mo median follow up achieves disease control rate (DCR) of 91.3% and objective response rate (ORR) of 56.5% for patients across all dose levels (DLs) and ORR of 75.0% at DL4

30-May-2024 9:00 AM EDT
ASCO: New ‘Armored’ CAR produces significant responses in patients whose cancers don't respond to current CAR T cell therapies
Perelman School of Medicine at the University of Pennsylvania

A new “armored” form of CAR T cell therapy may be able to help patients with non-Hodgkin lymphoma whose cancers do not respond to currently available CAR T cell therapies. The Phase I clinical trial was presented at the 2024 ASCO Annual Meeting.

Released: 1-Jun-2024 1:05 PM EDT
Multicancer detection tests, AI prediction tools for cancer among research topics presented by Ohio State at ASCO 2024
Ohio State University Wexner Medical Center

How artificial intelligence tools could help predict colon cancer aggressiveness and how the gut microbiome might provide clues to the rapid rise in colon cancers among young people are among dozens of research studies being presented by The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) at the 2024 American Society of Clinical Oncology annual meeting, which takes place May 31 through June 4 in Chicago, Illinois. Among other emerging health topics being discussed are the use of multicancer screening tests and how equity should be a critical point of consideration in the commercial development of these tools.

Released: 1-Jun-2024 8:05 AM EDT
Clinical trials show promise in treating central nervous system lymphoma, breast cancer, and glioblastoma
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute researchers are leading 3 separate studies with encouraging results in treating patients with central nervous system (CNS) lymphoma, breast cancer, and glioblastoma. These findings are among more than 80 studies presented at ASCO that are led by Dana-Farber-affiliated researchers.

31-May-2024 8:00 AM EDT
ASCO: Novel CAR T therapy and shorter targeted therapy durations show promise for patients with leukemia
University of Texas MD Anderson Cancer Center

Researchers from The University of Texas MD Anderson Cancer Center presented positive clinical results from two studies today at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

Newswise: Study Reveals Worse Clinical Outcomes in Breast Cancer Patients Who Reported Higher Pain and Stress
Released: 30-May-2024 4:25 PM EDT
Study Reveals Worse Clinical Outcomes in Breast Cancer Patients Who Reported Higher Pain and Stress
Roswell Park Comprehensive Cancer Center

Secondary analyses of a phase 3 clinical trial have revealed that breast cancer patients who reported high levels of pain and stress were more likely than their study peers to experience worse invasive disease-free survival (iDFS) and worse overall survival (OS).

Newswise: Study Shows Polygenic Risk Score (PGS) Could Predict Breast Cancer Survival Outcomes
Released: 30-May-2024 4:00 PM EDT
Study Shows Polygenic Risk Score (PGS) Could Predict Breast Cancer Survival Outcomes
Roswell Park Comprehensive Cancer Center

Data from a large prospective cohort study reveal that a polygenic risk score has the potential to predict survival outcomes in patients with breast cancer.

Released: 30-May-2024 3:05 PM EDT
Promising New Treatment for Patients with HR+ HER-2 Negative Metastatic Breast Cancer
Yale Cancer Center/Smilow Cancer Hospital

New research from Yale Cancer Center reveals first-of-its-kind data from a phase I study in patients with hormone receptor positive HER2-negative metastatic breast cancer. The results, which assess the safety and efficacy of a treatment known as PF-07248144, offer new hope for treating this aggressive type of breast cancer.



close
1.72572